JP2018512413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512413A5 JP2018512413A5 JP2017549326A JP2017549326A JP2018512413A5 JP 2018512413 A5 JP2018512413 A5 JP 2018512413A5 JP 2017549326 A JP2017549326 A JP 2017549326A JP 2017549326 A JP2017549326 A JP 2017549326A JP 2018512413 A5 JP2018512413 A5 JP 2018512413A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173052A JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510119944.5 | 2015-03-19 | ||
| CN201510119944.5A CN106146508A (zh) | 2015-03-19 | 2015-03-19 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| PCT/CN2016/000149 WO2016145935A1 (zh) | 2015-03-19 | 2016-03-18 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173052A Division JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512413A JP2018512413A (ja) | 2018-05-17 |
| JP2018512413A5 true JP2018512413A5 (https=) | 2019-04-04 |
| JP7012534B2 JP7012534B2 (ja) | 2022-02-14 |
Family
ID=56918303
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549326A Active JP7012534B2 (ja) | 2015-03-19 | 2016-03-18 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
| JP2021173052A Pending JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173052A Pending JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3272752A4 (https=) |
| JP (2) | JP7012534B2 (https=) |
| KR (2) | KR102428387B1 (https=) |
| CN (4) | CN106146508A (https=) |
| AU (2) | AU2016232923B2 (https=) |
| BR (1) | BR112017019790B1 (https=) |
| CA (2) | CA3191171A1 (https=) |
| EA (2) | EA037058B1 (https=) |
| IL (1) | IL254435B2 (https=) |
| MX (1) | MX2017011836A (https=) |
| WO (1) | WO2016145935A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2018090792A1 (zh) * | 2016-11-15 | 2018-05-24 | 杭州和正医药有限公司 | 一种选择性布鲁顿酪氨酸激酶抑制剂及其应用 |
| CN106831788B (zh) * | 2017-01-22 | 2020-10-30 | 鲁南制药集团股份有限公司 | 伊布替尼精制方法 |
| SG11202002218VA (en) * | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
| TW201922256A (zh) * | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| WO2019127008A1 (zh) * | 2017-12-26 | 2019-07-04 | 清华大学 | 一种靶向降解btk的化合物及其应用 |
| EP3746426A4 (en) * | 2018-01-29 | 2021-12-29 | Dana Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CN108992454B (zh) * | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
| CN114522167A (zh) * | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CN109369654A (zh) * | 2018-11-20 | 2019-02-22 | 山东大学 | 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用 |
| KR102819183B1 (ko) * | 2019-03-29 | 2025-06-13 | 한미약품 주식회사 | 퓨로피리미딘 화합물의 산 부가염의 결정형 |
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用 |
| CN110845500B (zh) * | 2019-10-09 | 2021-05-11 | 清华大学 | 靶向btk降解化合物在治疗自身免疫系统疾病中的应用 |
| US20230255975A1 (en) * | 2020-06-25 | 2023-08-17 | Celgene Corporation | Methods for treating cancer with combination therapies |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| BR112022025911A2 (pt) * | 2020-06-25 | 2023-01-10 | Tolremo Therapeutics Ag | Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| CA3196886A1 (en) * | 2020-11-04 | 2022-05-12 | Yoram Devary | Polypeptides for use in the treatment and prevention of neurodegenerative diseases |
| IL307402A (en) | 2021-04-07 | 2023-12-01 | Tolremo Therapeutics Ag | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer |
| CN114507236A (zh) * | 2022-02-28 | 2022-05-17 | 山东中医药大学 | mTOR蛋白降解靶向嵌合体及其制备方法和应用 |
| JP2025512487A (ja) * | 2022-04-12 | 2025-04-17 | 合肥▲優▼源▲薬▼▲業▼有限公司 | ピラゾロピリミジン化合物の新規な使用 |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN116024346A (zh) * | 2023-02-10 | 2023-04-28 | 复旦大学附属华山医院 | SLCO1B1 rs2306283位点多态性在评价甲氨蝶呤所致骨髓抑制发生风险中的应用 |
| CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| SG10202107066WA (en) * | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CA2730930C (en) * | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| JP6261580B2 (ja) | 2012-07-30 | 2018-01-17 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化イブルチニブ |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| NZ629456A (en) * | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2014187319A1 (en) * | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
-
2015
- 2015-03-19 CN CN201510119944.5A patent/CN106146508A/zh active Pending
-
2016
- 2016-03-18 JP JP2017549326A patent/JP7012534B2/ja active Active
- 2016-03-18 KR KR1020177025465A patent/KR102428387B1/ko active Active
- 2016-03-18 EA EA201792066A patent/EA037058B1/ru unknown
- 2016-03-18 WO PCT/CN2016/000149 patent/WO2016145935A1/zh not_active Ceased
- 2016-03-18 MX MX2017011836A patent/MX2017011836A/es unknown
- 2016-03-18 KR KR1020227026364A patent/KR20220110872A/ko not_active Ceased
- 2016-03-18 CN CN202111303221.2A patent/CN114790209A/zh active Pending
- 2016-03-18 CA CA3191171A patent/CA3191171A1/en active Pending
- 2016-03-18 EA EA202092671A patent/EA202092671A1/ru unknown
- 2016-03-18 EP EP16764117.4A patent/EP3272752A4/en active Pending
- 2016-03-18 BR BR112017019790-1A patent/BR112017019790B1/pt active IP Right Grant
- 2016-03-18 CN CN201680017009.0A patent/CN107406454B/zh active Active
- 2016-03-18 AU AU2016232923A patent/AU2016232923B2/en active Active
- 2016-03-18 IL IL254435A patent/IL254435B2/en unknown
- 2016-03-18 CA CA2980016A patent/CA2980016C/en active Active
- 2016-03-18 CN CN202010319886.1A patent/CN111349099A/zh active Pending
-
2020
- 2020-11-24 AU AU2020277128A patent/AU2020277128B2/en active Active
-
2021
- 2021-10-22 JP JP2021173052A patent/JP2022003103A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512413A5 (https=) | ||
| CN109803972A (zh) | 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 | |
| JP2015528020A5 (https=) | ||
| MX2021011472A (es) | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. | |
| JP2016533366A5 (https=) | ||
| PE20160995A1 (es) | Inhibidores de syk | |
| MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2015535277A5 (https=) | ||
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| RU2008122048A (ru) | Аминопиримины в качестве ингибиторов киназ | |
| JP2009514881A5 (https=) | ||
| JP2015535851A5 (https=) | ||
| GEAP202215377A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| HRP20180499T1 (hr) | Spojevi i postupci za modulaciju kinaze, te odgovarajuće indikacije | |
| JP2018535951A5 (https=) | ||
| CY1117067T1 (el) | Η χρηση σωματιδιων στερεων φορεων για τη βελτιωση της επεξεργασιμοτητας φαρμακευτικου παραγοντα | |
| HRP20171727T1 (hr) | Novi terapeutici | |
| TN2016000263A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| JP2016521280A5 (https=) | ||
| JP2015500884A5 (https=) | ||
| JP2017524668A5 (https=) | ||
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. |